"Designing Growth Strategies is in our DNA"

Cell and Gene Therapy Market Size, Share & Industry Analysis by Type (Cell Therapy {Therapy Type [CAR-T Cell Therapy, TCR-T Cell Therapy, Natural Killer (NK) Cells, and Others], Product Type [Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Others], Indication [Oncology and Others]} and Gene Therapy {Product Type [Zolgensma, Luxturna, Roctavian, and Others], Vector Type [Viral Vectors and Non-Viral Vectors], Indication [Genetic Disorders, Ophthalmology, Hematology, and Others]}), By End User (Hospitals & Clinics, Specialty Clinics, and Others), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI114130

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Development of Cell and Gene Therapy for New Disease Indications
    2. Regulatory Scenarios, By Key Countries/Regions
    3. Technological Advancements in the Market
    4. New Product Launches, By Key Players
    5. Pipeline Analysis, By Key Companies
    6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
    7. Pricing & Reimbursement Landscape in the Market
    8. Manufacturing & Supply Chain Insights
    9. Investment & Funding Trends in the Market
    10. Overview: Patient Access to the Therapy & Ethical Considerations 
  5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032 
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Germany 
      2. U.K.
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2024)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Vertex Pharmaceuticals Incorporated
      2. Krystal Biotech, Inc. 
      3. Rocket Pharmaceuticals 
      4. CRISPR Therapeutics
      5. Bayer AG
      6. Novartis AG
      7. Gilead Sciences, Inc.
      8. F. Hoffmann-La Roche Ltd (Spark Therapeutics) 
      9. Bristol-Myers Squibb Company
      10. Adaptimmune
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trends
  4. Key Insights
    1. Development of Cell and Gene Therapy for New Disease Indications
    2. Regulatory Scenarios, By Key Countries/Regions
    3. Technological Advancements in the Market
    4. New Product Launches, By Key Players
    5. Pipeline Analysis, By Key Companies
    6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
    7. Pricing & Reimbursement Landscape in the Market
    8. Manufacturing & Supply Chain Insights
    9. Investment & Funding Trends in the Market
    10. Overview: Patient Access to the Therapy & Ethical Considerations 
  5. Global Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032 
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – Region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country
      1. U.S.
      2. Canada 
  7. Europe Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Germany 
      2. U.K.
      3. France 
      4. Italy
      5. Spain
      6. Scandinavia
      7. Rest of Europe
  8. Asia Pacific Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. China
      2. Japan
      3. India
      4. Australia
      5. Southeast Asia
      6. Rest of Asia Pacific
  9. Latin America Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. Brazil
      2. Mexico
      3. Rest of Latin America
  10. Middle East & Africa Cell and Gene Therapy Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Type 
      1. Cell Therapy
        1. Therapy Type
          1. CAR-T Cell Therapy
          2. TCR-T Cell Therapy
          3. Natural Killer (NK) Cells
          4. Others
        2. Product Type
          1. Kymriah
          2. Yescarta
          3. Tecartus
          4. Breyanzi
          5. Abecma
          6. Carvykti
          7. Others
        3. Indication
          1. Oncology 
          2. Others
      2. Gene Therapy
        1. Product Type
          1. Zolgensma
          2. Luxturna
          3. Roctavian
          4. Others
        2. Vector Type
          1. Viral Vectors
          2. Non-Viral Vectors
        3. Indication
          1. Genetic Disorders 
          2. Ophthalmology 
          3. Hematology 
          4. Others
    2. Market Analysis, Insights and Forecast – By End User
      1. Hospitals & Clinics
      2. Specialty Clinics
      3. Others
    3. Market Analysis, Insights and Forecast – By Country/ Sub-Region
      1. GCC 
      2. South Africa
      3. Rest of Middle East & Africa
  11. Competitive Analysis 
    1. Global Market Share Analysis (2024)
    2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
      1. Vertex Pharmaceuticals Incorporated
      2. Krystal Biotech, Inc. 
      3. Rocket Pharmaceuticals 
      4. CRISPR Therapeutics
      5. Bayer AG
      6. Novartis AG
      7. Gilead Sciences, Inc.
      8. F. Hoffmann-La Roche Ltd (Spark Therapeutics) 
      9. Bristol-Myers Squibb Company
      10. Adaptimmune
Read Less

Figure 1: Global Cell and Gene Therapy Market Revenue Breakdown (USD Billion, %) by Region, 2024 & 2032

Figure 2: Global Cell and Gene Therapy Market Value Share (%), by Type, 2024 & 2032

Figure 3: Global Cell and Gene Therapy Market Value Share (%), by End User, 2024 & 2032

Figure 4: Global Cell and Gene Therapy Market Value (USD Billion), by Region, 2024 & 2032

Figure 5: North America Cell and Gene Therapy Market Value (USD Billion), by Type, 2024 & 2032

Figure 6: North America Cell and Gene Therapy Market Value Share (%), by Type, 2024

Figure 7: North America Cell and Gene Therapy Market Value (USD Billion), by End User, 2024 & 2032

Figure 8: North America Cell and Gene Therapy Market Value Share (%), by End User, 2024

Figure 9: North America Cell and Gene Therapy Market Value (USD Billion), By Country, 2024 & 2032

Figure 10: North America Cell and Gene Therapy Market Value Share (%), By Country, 2024

Figure 11: Europe Cell and Gene Therapy Market Value (USD Billion), by Type, 2024 & 2032

Figure 12: Europe Cell and Gene Therapy Market Value Share (%), by Type, 2024

Figure 13: Europe Cell and Gene Therapy Market Value (USD Billion), by End User, 2024 & 2032

Figure 14: Europe Cell and Gene Therapy Market Value Share (%), by End User, 2024

Figure 15: Europe Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2024 & 2032

Figure 16: Europe Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 17: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by Type, 2024 & 2032

Figure 18: Asia Pacific Cell and Gene Therapy Market Value Share (%), by Type, 2024

Figure 19: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), by End User, 2024 & 2032

Figure 20: Asia Pacific Cell and Gene Therapy Market Value Share (%), by End User, 2024

Figure 21: Asia Pacific Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2024 & 2032

Figure 22: Asia Pacific Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 23: Latin America Cell and Gene Therapy Market Value (USD Billion), by Type, 2024 & 2032

Figure 24: Latin America Cell and Gene Therapy Market Value Share (%), by Type, 2024

Figure 25: Latin America Cell and Gene Therapy Market Value (USD Billion), by End User, 2024 & 2032

Figure 26: Latin America Cell and Gene Therapy Market Value Share (%), by End User, 2024

Figure 27: Latin America Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2024 & 2032

Figure 28: Latin America Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 29: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by Type, 2024 & 2032

Figure 30: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by Type, 2024

Figure 31: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), by End User, 2024 & 2032

Figure 32: Middle East & Africa Cell and Gene Therapy Market Value Share (%), by End User, 2024

Figure 33: Middle East & Africa Cell and Gene Therapy Market Value (USD Billion), By Country/ Sub-region, 2024 & 2032

Figure 34: Middle East & Africa Cell and Gene Therapy Market Value Share (%), By Country/ Sub-region, 2024

Figure 35: Global Cell and Gene Therapy Market Share (%), By Company, 2024

Table 1: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 2: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 3: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 4: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 5: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 6: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 7: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 8: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 9: Global Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Region, 2019-2032

Table 10: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 11: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 12: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 13: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 14: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 15: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 16: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 17: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 18: North America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country, 2019-2032

Table 19: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 20: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 21: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 22: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 23: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 24: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 25: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 26: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 27: Europe Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2019-2032

Table 28: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 29: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 30: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 31: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 32: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 33: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 34: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 35: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 36: Asia Pacific Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2019-2032

Table 37: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 38: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 39: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 40: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 41: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 42: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 43: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 44: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 45: Latin America Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2019-2032

Table 46: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 47: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Therapy Type, 2019–2032

Table 48: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 49: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 50: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Product Type, 2019–2032

Table 51: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Vector Type, 2019–2032

Table 52: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by Indication, 2019–2032

Table 53: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, by End User 2019–2032

Table 54: Middle East & Africa Cell and Gene Therapy Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2019-2032

Cell and Gene Therapy Market
  • 2019-2032
  • 2024
  • 2019-2023
  • 220
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports